SAN FRANCISCO--(BUSINESS WIRE)--Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has appointed Dr. Victoria Lewis as Chief of Clinical Development. Dr. Lewis will oversee the planning, strategic development, and operation of the Company’s expanding clinical initiatives.
Dr. Lewis has spent 30 years in drug development, including 15 years developing drugs in the animal health space. She began her career at Novartis (Sandoz Inc.), followed by Serono Laboratories and Parexel International Corporation. Upon receiving her doctorate in veterinary medicine, Dr. Lewis joined Schering-Plough Animal Health (now Merck Animal Health), where she held management positions as the company evolved through its merger with Intervet and subsequent acquisition by Merck. Most recently, she held a senior management position at AlcheraBio, a contract research organization. Dr. Lewis' experience in all phases of clinical trials, regulatory affairs and strategic planning has led to the approval of multiple new animal drugs as well as expanded label claims of previously approved products.
Dr. Lewis earned a B.S. in Pharmacy from the Massachusetts College of Pharmacy and a doctorate in veterinary medicine from Tufts University School of Veterinary Medicine.
“The addition of Dr. Lewis to our team comes at an exciting time for Jaguar as we progress with the development of new and innovative products for the companion and production animal markets. We have a number of ongoing clinical programs, with more slated to begin in the near-term,” stated Lisa Conte, Jaguar’s President and CEO. “Dr. Lewis’ breadth of industry and leadership experience will be a tremendous asset to our team as we take further steps toward commercialization.”
“I am excited to join the Jaguar team and support the clinical activities around the Company’s robust pipeline of gastrointestinal products for companion and production animals worldwide. The Company is uncompromising in its efforts to develop solutions for a number of unaddressed gastrointestinal needs in the market. I look forward to leveraging my industry knowledge with the team’s extensive background in gastrointestinal and animal health to bring innovative prescription and non-prescription products to a rapidly growing market,” commented Dr. Lewis.
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals. Canalevia™ is Jaguar’s lead prescription drug product candidate for the treatment of various forms of watery diarrhea in dogs. Neonorm™ Calf is the Company’s lead non-prescription product. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm is a standardized botanical extract derived from the Croton lechleri tree. Canalevia and Neonorm are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has filed nine Investigational New Animal Drug applications, or INADs, with the FDA and intends to develop species-specific formulations of Neonorm in six additional target species, and formulations of Canalevia for cats, horses and dogs.
For more information, please visit www.jaguaranimalhealth.com.